Agile Therapeutics, Inc. (AGRX) Expected to Post Earnings of -$0.25 Per Share
Wall Street analysts predict that Agile Therapeutics, Inc. (NASDAQ:AGRX) will report earnings per share of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.21). Agile Therapeutics posted earnings per share of ($0.27) in the same quarter last year, which would suggest a positive year-over-year growth rate of 7.4%. The firm is scheduled to report its next earnings report on Monday, November 6th.
According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.06) to ($0.98). For the next financial year, analysts expect that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($1.28) to ($0.09). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same period last year, the firm earned ($0.29) earnings per share.
Several analysts have recently commented on AGRX shares. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. ValuEngine lowered shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Royal Bank Of Canada increased their price target on shares of Agile Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday. Janney Montgomery Scott reaffirmed a “buy” rating and set a $13.00 price target on shares of Agile Therapeutics in a research note on Thursday, September 7th. Finally, HC Wainwright started coverage on shares of Agile Therapeutics in a research note on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $9.08.
Shares of Agile Therapeutics (NASDAQ AGRX) opened at 3.83 on Friday. The firm’s market capitalization is $110.33 million. The company has a 50-day moving average price of $3.56 and a 200 day moving average price of $3.45. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.95.
In related news, Chairman Alfred Altomari purchased 10,000 shares of the company’s stock in a transaction on Friday, August 25th. The shares were bought at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the transaction, the chairman now owns 161,587 shares of the company’s stock, valued at $539,700.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGRX. Royce & Associates LP increased its position in shares of Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock worth $3,745,000 after acquiring an additional 11,000 shares in the last quarter. Royal Bank of Canada grew its position in Agile Therapeutics by 608.0% during the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in Agile Therapeutics during the second quarter valued at approximately $122,000. Susquehanna International Group LLP purchased a new position in Agile Therapeutics during the second quarter valued at approximately $205,000. Finally, LMR Partners LLP purchased a new position in Agile Therapeutics during the second quarter valued at approximately $211,000. Institutional investors and hedge funds own 67.59% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.